ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.

We expect to market our products in North America but recognize the importance of commercial partnerships should our early clinical trial results support cancer treatment with high incidence and prevalence.

We currently have three products in clinical development.

Darinaparsin (ZIO-101) is in a Phase II trial in patients with advanced myeloma, patients with primary liver cancer and patients with diverse hematological malignancies, and a Phase I trial has also begun involving oral administration. Palifosfamide (ZIO-201) is in late Phase II clinical trials in patients with advanced sarcoma and various advanced cancers, and a Phase I/II sarcoma combination trial is now underway. Indibulin (ZIO-301) is currently in a late Phase I trial in Europe and the United States, and a Phase I/II combination trial has been initiated.